As a small molecular inhibitor that targets a number of serine/threonine and receptor tyrosine kinases, sorafenib (Nexavar or BAY 43-9006) is the first oral agent approved for the clinical treatment of a variety of tumor types [10], [11]. This evidence concerns the gene NTRK1 and neoplasm.